Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial

Abstract

Background: The most leading cause of death in end-stage renal disease (ESRD) patients are cardiovascular disease and inflammatory markers are related to coronary events. CO-Q10 (coenzyme Q10) is a protective supplement from free radical oxidative damage. In addition, hyperhomocysteinemia is an independent coronary artery disease (CAD) risk factor. Objectives: Due to increasing oxidative stress in dialysis patients, and the effect of CO-Q10 in decrease oxidative stress, in this work, we assessed the effect of CO-Q10 on C-reactive protein (CRP) level as an inflammatory marker and homocysteine in dialysis patients. Patients and Methods: This was a single-blind, randomized cross over clinical trial. Patients with ESRD were randomly allotted to two groups. All patients received placebo and C0- Q10 100mg/d during the three months in each stage, with two week washout period. Plasma level of CRP and homocysteine from the start of the work and at the conclusion of each menses, are evaluated. Results: Thirty-four patients randomized, but 26 patients complete study protocol. The treatment effect of CO-Q10 on CRP level is significant (P < 0.001) (95% CI = -20.1 to -10.5) and it was also significant for the increasing albumin level. (P = 0.044) (95% CI = 0. 0-0.6), But there was not any substantial effect on serum homocysteine level (P = 0.630). Conclusions: CO-Q10 could significantly decrease CRP level as an inflammatory marker and can protect cardiovascular events.

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

“…Finally, a recent meta-analysis of 4 RCTs and 4 experimental studies of diabetic people revealed that CoQ 10 CoQ 10 supplementation for diabetic hemodialysis patients for 12 weeks did not influence lipid profiles [70,146,147]. In hemodialysis patients, 100 mg/day of CoQ 10 for 3 months could significantly reduce CRP levels (95%CI = −20.1 to −10.5, p < 0.001) [148], while daily supplementation with 1200 mg of CoQ 10 significantly improved biomarkers of oxidative stress [149].…”

Chronic kidney disease and coenzyme Q10 supplementation

“…A number of clinical studies have reported that supplementation with CoQ10 significantly improves outcome in haemodialysis patients by reducing markers of oxidative stress and inflammation. In a randomised controlled trial, Zahed et al (Zahed et al, 2016) reported that CoQ10 supplementation (100mg/day for 3 months) in end stage CKD patients undergoing haemodialysis significantly reduced serum levels of the inflammatory marker C-reactive protein. An open label dose escalation study by Yeung et al (2015) showed supplementation with CoQ10 over the range 300-1800mg/day for 14 days to be safe and well tolerated, significantly reducing plasma levels of the oxidative stress marker isofuran.…”

The effect of coenzyme Q10 on cognitive status in chronic hemodialysis patients; a double-blind, randomized, clinical trial

“…Other studies have also compared the patients' cognitive status with a control group using the MMSE; in this study, however, since the aim was to determine the effect of CoQ10 supplement on dialysis patients' cognitive status, the MMSE scores of the supplement group were not compared with a non-dialysis control group, rather, the changes in the cognitive status of hemodialysis patients under the effect of CoQ10 supplement were compared with a hemodialysis group that did not receive this supplement. Previous studies have also addressed the effect of CoQ10 supplementation in preventing the progress of renal disease and have reported positive effects for this supplement (39)(40)(41)(42).…”